Powder: -20°C for 3 years | In solvent: -80°C for 1 year
1. Fargesin ((+/-)-Fargesin) as a potential β1AR antagonist through cAMP/PKA pathway could protect against myocardial ischemia/reperfusion injury in rats. 2. Fargesin improves dyslipidemia and hyperglycemia by activating Akt and AMPK in WAT.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 195.00 | |
50 mg | In stock | $ 319.00 | |
100 mg | In stock | $ 475.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | 1. Fargesin ((+/-)-Fargesin) as a potential β1AR antagonist through cAMP/PKA pathway could protect against myocardial ischemia/reperfusion injury in rats. 2. Fargesin improves dyslipidemia and hyperglycemia by activating Akt and AMPK in WAT. |
Source |
Synonyms | (+/-)-Fargesin |
Molecular Weight | 370.4 |
Formula | C21H22O6 |
CAS No. | 31008-19-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33 mg/mL(89.1 mM)
Chloroform, Dichloromethane, Ethyl Acetate, Acetone, etc.: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fargesin 31008-19-2 GPCR/G Protein Neuroscience Adrenergic Receptor inhibit Inhibitor (+/-)-Fargesin inhibitor